Trials / Terminated
TerminatedNCT03029104
Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2,228 (actual)
- Sponsor
- Cxlusa · Industry
- Sex
- All
- Age
- 8 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.
Detailed description
This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all patients receive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | CXLO Corneal Strengthening Solution and UVA Illumination Device | CXLO Corneal Strengthening Solution |
Timeline
- Start date
- 2016-12-21
- Primary completion
- 2020-12-27
- Completion
- 2020-12-27
- First posted
- 2017-01-24
- Last updated
- 2022-01-12
- Results posted
- 2022-01-12
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03029104. Inclusion in this directory is not an endorsement.